GE HealthCare Technologies (STU:L0T) Notes Receivable: €0 Mil (As of Mar. 2026)


STU:L0T GE HealthCare Technologies Inc STU:L0T
68 GF Score
Price €56.68
GF Value €73.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is GE HealthCare Technologies Notes Receivable?

GE HealthCare Technologies STU:L0T +0.21% 68 Notes Receivable is €0 Mil as of Mar. 2026. GuruFocus rates STU:L0T with a GF Score™ of 68/100 and a GF Value™ of €73.91 (Modestly Undervalued). The stock has 4 warning signs investors should review.

GE HealthCare Technologies's Notes Receivable for the quarter that ended in Mar. 2026 was €0 Mil.

GE HealthCare Technologies Notes Receivable Related Terms

GE HealthCare Technologies Notes Receivable Historical Data

* Premium members only.

The historical data trend for GE HealthCare Technologies's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GE HealthCare Technologies Notes Receivable Chart

GE HealthCare Technologies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

GE HealthCare Technologies Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:L0T
68GF Score
GE HealthCare Technologies Inc STU:L0T
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GE HealthCare Technologies Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0 Mil mean?
GE HealthCare Technologies (STU:L0T) has a Notes Receivable of €0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on GE HealthCare Technologies and its competitors.
Is GE HealthCare Technologies' Notes Receivable too high?
GE HealthCare Technologies' current Notes Receivable is €0 Mil. Overall, GE HealthCare Technologies has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' Notes Receivable compare to DXCM and STE?
GE HealthCare Technologies' Notes Receivable of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on GE HealthCare Technologies and its competitors. GE HealthCare Technologies's current Notes Receivable is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (STU:L0T) is currently considered Modestly Undervalued. The stock's GF Value™ is €73.91, compared to a current price of €56.68 — trading 23.3% below its estimated fair value. The current Notes Receivable is €0 Mil. GE HealthCare Technologies' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For GE HealthCare Technologies (STU:L0T), the current Notes Receivable is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GE HealthCare Technologies (STU:L0T) Overvalued in 2026?

Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued. The current stock price of €56.68 is trading 23.3% below its estimated GF Value™ of €73.91. GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.

Key valuation signals for STU:L0T:

  • Notes Receivable: €0 Mil
  • GF Value™: €73.91 vs. price of €56.68 (23.3% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the STU:L0T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GE HealthCare Technologies Business Description

Address 500 West Monroe Street, Chicago, IL, USA, 60661
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
68GF Score

Get the complete analysis for STU:L0T

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.68
Price
€73.91
GF Value